Caremark Rx — Merger or Acquisition (January 2007)
24 slides from Caremark Rx's merger presentation, Jan 10, 2007
Slide 1: Filed by Caremark Rx, Inc. Pursuant to Rule 425
1 Filed by Caremark Rx, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and Deemed Filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Caremark Rx, Inc. Commission File No.: 001-14200
Slide 2: Creating the Premier Pharmaceutical Services and Integrated Healthcare Provider
2 Mac Crawford Chairman, President and CEO JP Morgan 25 Annual Healthcare Conference January 10, 2007 th Creating the Premier Pharmaceutical Services and Integrated Healthcare Provider
Slide 3: Forward-looking statements
3 This document contains certain forward-looking statements about Caremark and CVS. When used in this document, the words “anticipates”, “may”, “can”, “believes”, “expects”, “projects”, “intends”, “likely”, “will”, “to be” and any similar expressions and any other statements that are not historical
Slide 4: Additional information about the proxy statement/prospectus
4 Caremark and CVS filed a joint proxy statement/prospectus with the SEC in connection with the proposed merger. Caremark and CVS urge investors and stockholders to read the joint proxy statement/prospectus and any other relevant documents filed by either party with the SEC because they contain impo
Slide 5: Express Scripts Proposal Not in Best Interests
5 No strategic benefits Financial benefits are illusory Risk of antitrust delay likely Significant business risk Diminished financial flexibility Integration track record questionable Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers
Slide 6: Express Scripts Proposal: Strategic Rationale
6 Does not create competitive advantages Defensive reaction out of concern about enhanced competition Constructed to disrupt CVS/Caremark merger Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Strategic Rationale
Slide 7: Express Scripts Proposal: Financial Risk
7 Lost business & negative synergies could offset purported synergies Synergy calculation questionable Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Financial Risk Does not create competitive advantages Defensive reaction out of concern about enhanced compet
Slide 8: Express Scripts Proposal: Antitrust Risk
8 Delay will destroy 2007 and perhaps 2008 selling season Enforcement agencies could impose adverse conditions Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Antitrust Risk Lost business & negative synergies could offset purported synergies Synergy calculatio
Slide 9: Express Scripts Proposal: Business Risk
9 Clients overwhelmingly negative Risk of substantial client attrition Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Business Risk Delay will destroy 2007 and perhaps 2008 selling season Enforcement agencies could impose adverse conditions Antitrust Risk Los
Slide 10: Express Scripts Proposal: Financial Position
10 Limited capital for investment in existing business, strategic opportunities, dividends and share repurchases ESRX recently placed on negative watch by rating agencies Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Financial Position Clients overwhelmingly
Slide 11: Express Scripts Proposal: Management Team
11 No experience with large-scale merger integration Recent integration track-record questionable Express Scripts Proposal Not in Best Interests of Shareholders, Customers and Consumers Management Team Limited capital for investment in existing business, strategic opportunities, dividends and share
Slide 12: Express Scripts Proposal Not in Best Interests (summary)
12 No experience with large-scale merger integration Recent integration track-record questionable Limited capital for investment in existing business, strategic opportunities, dividends and share repurchases ESRX recently placed on negative watch by rating agencies Clients overwhelmingly negative Ri
Slide 13: Value: CVS merger versus Express Scripts
13 • Significant strategic benefit • Solid financial benefits • Clients supportive • Q1 Close • Strong management team • No strategic advantage • Financial benefits suspect • Client attrition • Q3 close or later • Questionable recent performance & integrations Value
Slide 14: CVS/Caremark Merger Capitalizes on Evolving Industry Trends
14 CVS Merger Benefit Market Trends CVS/Caremark Merger Capitalizes on Evolving Industry Trends In store enrollment and consultation; Medication Therapy Management Medicare Part D More transparency at point of sale - consumer able to make totally informed decisions Cost Shift to Consumer Retail loca
Slide 15: CVS/Caremark Merger is in Best Interest
15 Significant strategic benefits Financial benefits are concrete and conservative No antitrust risk Business disruption minimal Enhanced financial position Proven management teams CVS/Caremark Merger Enhances Shareholder Value CVS/Caremark Merger is in Best Interest of Shareholders, Customers and C
Slide 16: Strategic Benefits
16 Logical evolution to better serve customers Caremark will be an even more effective PBM Will create differentiated services CVS/Caremark Merger Enhances Shareholder Value Strategic Benefits
Slide 17: Financial Benefits
17 At least $500 million in validated cost synergies with additional cost and revenue synergy opportunities CVS/Caremark Merger Enhances Shareholder Value Financial Benefits Logical evolution to better serve customers Caremark will be an even more effective PBM Will create differentiated services St
Slide 18: Antitrust Status
18 HSR period expired 12/20/06 – no risk CVS/Caremark Merger Enhances Shareholder Value Antitrust Status At least $500 million in validated cost synergies with additional cost and revenue synergy opportunities Financial Benefits Logical evolution to better serve customers Caremark will be an even mo
Slide 19: Business Opportunity
19 Clients overwhelmingly positive Could enhance selling season results Minimal integration risk CVS/Caremark Merger Enhances Shareholder Value Business Opportunity HSR period expired 12/20/06 – no risk Antitrust Status At least $500 million in validated cost synergies with additional cost and reven
Slide 20: Financial Flexibility
20 Flexibility for investments in existing business, strategic opportunities, dividends and share repurchases CVS/Caremark Merger Enhances Shareholder Value Financial Flexibility Clients overwhelmingly positive Could enhance selling season results Minimal integration risk Business Opportunity HSR pe
Slide 21: Management Teams
21 Proven track-records with large scale acquisition integration History of exceeding stated synergies Visionary leadership CVS/Caremark Merger Enhances Shareholder Value Flexibility for investments in existing business, strategic opportunities, dividends and share repurchases Financial Flexibility
Slide 22: CVS/Caremark Merger Benefits Summary
22 Flexibility for investments in existing business, strategic opportunities, dividends and share repurchases Proven track-records with large scale acquisition integration History of exceeding stated synergies Visionary leadership Clients overwhelmingly positive Minimal integration risk Expect Q1 cl
Slide 23: Board conclusion on Express Scripts proposal
23 Our Board gave careful consideration to the Express Scripts proposal. In the end, our conclusion was simple and straightforward: Express’ proposal is not in the best interests of Caremark, its shareholders, customers and consumers. Caremark believes that future success does not lie in simply crea
Slide 24: Creating the Premier Pharmaceutical Services and Integrated Healthcare Provider
24 Mac Crawford Chairman, President and CEO JP Morgan 25 Annual Healthcare Conference January 10, 2007 th Creating the Premier Pharmaceutical Services and Integrated Healthcare Provider